Hims & Hers Health (NYSE:HIMS) CFO Oluyemi Okupe Sells 4,938 Shares

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 4,938 shares of the business’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $29.99, for a total transaction of $148,090.62. Following the sale, the chief financial officer directly owned 264,117 shares in the company, valued at approximately $7,920,868.83. This represents a 1.84% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Oluyemi Okupe also recently made the following trade(s):

• On Thursday, June 18th, Oluyemi Okupe sold 55,383 shares of Hims & Hers Health stock. The stock was sold at an average price of $35.09, for a total transaction of $1,943,389.47.
• On Monday, August 17th, Oluyemi Okupe sold 9,388 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.89, for a total transaction of $261,831.32.
• On Monday, July 6th, Oluyemi Okupe sold 7,163 shares of Hims & Hers Health stock. The stock was sold at an average price of $36.49, for a total transaction of $261,377.87.
• On Monday, June 22nd, Oluyemi Okupe sold 18,197 shares of Hims & Hers Health stock. The shares were sold at an average price of $34.03, for a total transaction of $619,243.91.

Hims & Hers Health Price Performance

NYSE HIMS opened at $31.95 on Friday. The company has a debt-to-equity ratio of 4.21, a current ratio of 0.93 and a quick ratio of 0.87. The stock’s fifty day moving average price is $32.23 and its 200 day moving average price is $26.09. Hims & Hers Health, Inc. has a 1 year low of $13.74 and a 1 year high of $65.30. The company has a market cap of $7.45 billion, a price-to-earnings ratio of -50.71 and a beta of 2.40.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, August 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.32). Hims & Hers Health had a negative return on equity of 6.51% and a negative net margin of 5.51%.The firm had revenue of $753.21 million during the quarter, compared to analysts’ expectations of $698.90 million. During the same quarter last year, the business earned $0.17 EPS. The business’s revenue was up 38.2% on a year-over-year basis. As a group, equities research analysts forecast that Hims & Hers Health, Inc. will post -0.05 earnings per share for the current year.

Key Stories Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: CEO Andrew Dudum defended Hims & Hers against the FTC’s allegations and said the company’s strategy could improve patient access and affordability. He also discussed a potential AI health coach that could support medication adherence, creating a possible long-term technology catalyst. Hims & Hers rejects privacy allegations
• Positive Sentiment: Some investors continue to view the recent margin weakness as an opportunity, citing Hims & Hers’ 38.2% year-over-year revenue growth and potential expansion into testosterone, peptides, branded GLP-1 treatments and international markets. However, execution and profitability remain important hurdles. Hims & Hers: Buying the Margin Dip
• Neutral Sentiment: Recent insider filings show sales by CFO Oluyemi Okupe, Deborah M. Autor and Soleil Boughton. The transactions were conducted under pre-arranged Rule 10b5-1 plans, and several sales were intended to cover tax obligations from vested equity awards. Because insiders retained substantial positions, the filings are a limited bearish signal rather than clear evidence of weakening confidence. SEC insider transaction filing
• Neutral Sentiment: Analyst sentiment remains mixed. The consensus rating is “Hold,” while Needham raised its price target to $42 and maintained a Buy rating. The split view reflects strong sales growth but concerns about losses, margins and the GLP-1 business strategy.
• Negative Sentiment: The FTC litigation and new investigations by Kaplan Fox and Berger Montague add potential legal costs, compliance requirements and reputational risk. The investigations focus on alleged sharing of private health data, deceptive billing and difficult subscription cancellations, keeping regulatory uncertainty over the stock. Kaplan Fox investigation
• Negative Sentiment: Hims & Hers’ latest quarter showed a larger-than-expected loss of $0.37 per share versus the $0.05 consensus estimate, despite revenue exceeding expectations. The earnings miss and negative profitability metrics could limit the stock’s upside until margins improve.

Wall Street Analyst Weigh In

HIMS has been the subject of a number of research reports. Wall Street Zen raised Hims & Hers Health from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. TD Cowen increased their price target on shares of Hims & Hers Health from $25.00 to $30.00 and gave the stock a “hold” rating in a report on Tuesday, August 11th. Barclays raised their price target on shares of Hims & Hers Health from $29.00 to $39.00 and gave the stock an “overweight” rating in a research report on Wednesday, June 17th. BTIG Research restated a “neutral” rating on shares of Hims & Hers Health in a research note on Tuesday, May 12th. Finally, Citigroup dropped their price objective on shares of Hims & Hers Health from $35.00 to $33.00 and set a “neutral” rating on the stock in a report on Tuesday, August 11th. Four equities research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $32.43.

Hedge Funds Weigh In On Hims & Hers Health

Several institutional investors and hedge funds have recently modified their holdings of the stock. Binnacle Investments Inc acquired a new stake in Hims & Hers Health during the third quarter worth about $28,000. Versant Capital Management Inc boosted its position in Hims & Hers Health by 801.2% in the 2nd quarter. Versant Capital Management Inc now owns 748 shares of the company’s stock worth $26,000 after purchasing an additional 665 shares in the last quarter. MassMutual Private Wealth & Trust FSB boosted its position in Hims & Hers Health by 70.0% in the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 775 shares of the company’s stock worth $27,000 after purchasing an additional 319 shares in the last quarter. Silicon Valley Capital Partners acquired a new stake in shares of Hims & Hers Health during the 3rd quarter worth approximately $48,000. Finally, Bogart Wealth LLC grew its stake in shares of Hims & Hers Health by 235.8% during the 4th quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock worth $29,000 after purchasing an additional 632 shares during the period. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.